Seeking Alpha
 

Abbott Laboratories (ABT)

- NYSE
  • Jun. 20, 2012, 11:09 AM
    Abbott Labs (ABT -0.3%) is attempting to secure debt facilities of $14.5B to refinance existing debt and to smooth its separation into two listed companies, Reuters reports. Leading the deal, which will be the biggest loan package this year so far, are Merrill Lynch (BAC), Barclays (BCS), JP Morgan (JPM) and Morgan Stanley (MS).
    | 2 Comments
  • Jun. 11, 2012, 1:36 PM
    "It is very clear that Abbott Labs (ABT +0.2%) is the place to be when it comes to U.S. pharma stocks, with both dividends and earnings growth," writes SA author Tradevestor. Although Abbott's 3.3% yield "is the lowest of all the big pharma names," the firm has raised its dividend an average of 9% over the past five years, which is better than its peers.
    | 2 Comments
  • Jun. 6, 2012, 10:21 AM
    The $7.9B that Abbott (ABT) earned from arthritis drug Humira last year could be at risk after Roche's (RHHBY.PK) Actemra performed better in a trial of patients who couldn't take methotrexate. In another study, Bristol-Myers' (BMY) Orencia performed as well as Humira in patients who hadn’t taken a biological rheumatoid arthritis treatment before.
    | Comment!
  • Jun. 5, 2012, 10:23 AM
    Abbott Labs (ABT) and Neurocrine Biosciences (NBIX) are starting a 24-week Phase III trial of elagolix, a treatment for endometriosis, which is a debilitating gynecological disease that affects around 100M women worldwide and can cause infertility. (PR)
    | Comment!
  • Jun. 4, 2012, 11:48 AM
    Abbott Labs (ABT -0.4%) opens its first nutrition R&D center in India, which, with widespread malnutrition and the largest diabetes population in the world, is "a growth area" for the company. Abbot will therefore explore manufacturing nutrition products and boosting its sales and distribution ops in the country.
    | 1 Comment
  • May 7, 2012, 12:56 PM
    Abbott Labs (ABT -0.1%) reaches an $800M settlement with the government to resolve all outstanding issues regarding an investigation of past sales and marketing practices relating to its neurologic medication Depakote. The settlement stems from a four-year-old investigation into past sales activities, dating as far back as 1998. Additionally, the pharmaceutical giant says it will split into two separately traded companies.
    | Comment!
  • Apr. 24, 2012, 6:20 AM
    Nestle (NSRGY.PK) may sell $1.2B-$1.8B worth of assets from the infant-nutrition unit that it's buying from Pfizer for $11.85B in order to allay antitrust concerns in countries around the world, Bloomberg reports. Potential suitors could include Heinz (HNZ), Abbot Labs (ABT) and P-E funds.
    | Comment!
  • Apr. 18, 2012, 7:59 AM
    More on Abbott Laboratories' (ABT) Q1: Segment revenue gains led by Proprietary Pharmaceuticals (+6.6%), Nutritionals (+11%), and Core Laboratory Diagnostics (+12.8%). Says it's on track to separate into two companies by year end. Raises its outlook for full-year 2012 EPS to $5.00-$5.10, from prior guidance of $4.95-$5.05. Shares +1.3% premarket. (PR)
    | Comment!
  • Apr. 18, 2012, 7:47 AM
    Abbott Laboratories (ABT): Q1 EPS of $1.03 beats by $0.03. Revenue of $9.46B (+4.6% Y/Y) beats by $90M. (PR)
    | Comment!
  • Apr. 18, 2012, 12:05 AM
    Notable earnings before Wednesday's open: ABT, AMLN, ASML, BK, HAL, HBAN, NYB, PNC, STJ, TXT
    | Comment!
  • Apr. 17, 2012, 5:30 PM
    Notable earnings before Wednesday's open: ABT, AMLN, ASML, BK, HAL, HBAN, NYB, PNC, STJ, TXT
    | Comment!
  • Apr. 17, 2012, 4:10 PM
    Abbott Labs (ABT) says the results from its Phase 3 trial evaluating levodopa-carbidopa intestinal gel, its investigational compound for advanced Parkinson's disease, showed that patients reported clinically meaningful and statistically significant improvements compared to levodopa-carbidopa immediate release tablets.
    | Comment!
  • Apr. 11, 2012, 12:34 PM
    Abbott Laboratories' (ABT +0.4%) top-selling arthritis drug Humira is approved in Europe for moderate to severe ulcerative colitis. The decision makes Humira the first and only self-injectable biologic therapy for ulcerative colitis, and marks the seventh indication for the therapy in the EU since the product's first approval in 2003.
    | 1 Comment
  • Apr. 4, 2012, 12:48 PM
    Shares of Idenix Pharmaceuticals (IDIX -12.2%) sink after Abbott Laboratories (ABT +0.6%) releases positive results from studies of its experimental hepatitis C treatment. Other Hep-C companies vying for a piece of the rapidly-growing multi-billion dollar market: Gilead Sciences (GILD -2.2%), Vertex Pharmaceuticals (VRTX -1.2%), Bristol-Myers Squibb (BMY -0.5%), BioCryst Pharmaceuticals (BCRX -3.4%).
    | 1 Comment
  • Apr. 4, 2012, 12:36 PM
    Abbott Laboratories (ABT +0.5%) announces that studies of its experimental hepatitis C drug showed it suppressed the virus in most patients. If further studies follow through with positive results, the company plans to launch a new hepatitis C regimen in 2015.
    | Comment!
  • Mar. 28, 2012, 6:23 PM
    Myriad Genetics (MYGN) signs an agreement with Cephalon, a subsidiary of Teva Pharmaceutical (TEVA), to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in a Phase I/II clinical study. Myriad has entered into similar agreements with Abbott (ABT), Astra Zeneca (AZN) and BioMarin (BMRN) to provide similar diagnostic testing.
    | Comment!
Visit Seeking Alpha's
ABT vs. ETF Alternatives
Company Description
Abbott Laboratories discovers, develops, manufactures and sells health care products. Its products include branded generic pharmaceuticals manufactured internationally, marketed and sold outside the United States.